Publications

Clinical Study Journal Article Ppublish 4 citations

PubMed: 30222364 DOI: 10.1089/acm.2018.0311

Prospective Safety Evaluation of a Cardiovascular Health Dietary Supplement in Adults with Prehypertension and Stage I Hypertension.

J Altern Complement Med 25(2):249-256

Authors: Jennifer Joan Ryan, Douglas Allen Hanes, Jamie Corroon, Jan Taylor, Ryan Bradley

Affiliations

  • 1 Helfgott Research Institute, National University of Natural Medicine, Portland, OR.
  • 2 Family Medicine and Public Health, University of California, San Diego, La Jolla, CA.
  • 3 Australian Research Centre on Complementary and Integrative Medicine (ARCCIM), University of Technology Sydney, Ultimo, New South Wales, Australia.

Abstract

OBJECTIVE

To prospectively examine the long-term safety of a cardiovascular health dietary supplement by assessing a comprehensive set of safety measures.

DESIGN

Single-arm, open-label study.

LOCATION

National University of Natural Medicine, Portland, OR.

SUBJECTS

Thirty adults with screening blood pressure readings consistent with prehypertension or stage I hypertension.

INTERVENTION

One caplet per day of a dietary supplement for 6 months. The investigated herbal-mineral supplement contains several ingredients, most notably Rauwolfia serpentina.

OUTCOME MEASURES

Primary measures included b-type natriuretic peptide (NT-proBNP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), estimated glomerular filtration rate (eGFR), electrolytes, and the Patient Health Questionnaire (PHQ-9). Exploratory measures included physical vital signs, cholesterol levels, high-sensitivity cardiac troponin-I, cystatin C, endothelin, interleukin (IL)-6, IL-17a, tumor necrosis factor-α, high-sensitivity C-reactive protein, blood counts, and the Patient Reported Outcome Measure Information System (PROMIS) Sleep Disturbance Short Form 8b.

RESULTS

NT-proBNP, AST, ALT, eGFR, sodium, calcium, magnesium, PHQ-9 score, and the majority of exploratory measures did not change. However, serum potassium increased (p < 0.05), systolic blood pressure decreased (p < 0.0001), and diastolic blood pressure decreased (p < 0.0001). There were no serious adverse events, but 30% of participants withdrew citing potential side effects, most commonly nasal congestion or fatigue; most participants who reported nasal congestion also reported concomitant seasonal allergies. Adherence to the supplement was 90.9%.

CONCLUSIONS

The findings of this study suggest that the investigated dietary supplement is safe for long-term use in adults with prehypertension and stage I hypertension. Additional results of this study, particularly the increase in serum potassium and decreases in systolic and diastolic blood pressure, are promising and suggest that future research on this dietary supplement, or its ingredients, should further explore effects on blood pressure and biologic mechanisms of action, which may involve potassium-sparing and diuretic effects.

MeSH

Hypertension, Safety, Blood, Serum, C-Reactive Protein, Blood Pressure, Dietary Supplements, Transaminases, Prehypertension

Cited by